SOURCE: NeutriSci International

NeutriSci International Inc.

April 27, 2016 09:00 ET

NeutriSci Announces Results of AGM, Adds John Bell and Arlene Dickinson to Board

VANCOUVER, BC--(Marketwired - April 27, 2016) - NeutriSci International Inc. (the "Company" or "NeutriSci") (TSX VENTURE: NU) the innovator and pioneer behind neuenergy™, is pleased to announce the results of its Annual General Meeting ("AGM") held on April 22, 2016. Glen Rehman, President, commented, "I would like to thank our shareholders for their continued support, our board of directors for their guidance over the past year, and our employees for their dedication to NeutriSci. We are all committed to creating value for our shareholders by ensuring that our core product, neuenergy™, becomes widely known and accepted as the natural and health-conscious choice in the energy products market."

The number of directors has been set at seven and includes the re-election of Glen Rehman, Jeff Durno, Paula Rogers, Anthony Hugens and Dana Montenegro, and the election of new directors, John Bell and Arlene Dickinson.

John Bell is an entrepreneur at heart and brings a wealth of experience across a number of industries. Currently the Principal at Onbelay Capital Inc., John has also held executive and corporate leadership roles at Shred-Tech, Polymer Technologies, ATS Automation and BSM Wireless. John's volunteer roles include Chair of the Waterloo Police Commission, Chair of Cambridge Memorial Hospital, Chair of Waterloo Region prosperity council and Secretary of Crohns and Colitis Canada.

John founded Shred-Tech and grew it into a global giant in the mobile document shredding and recycling industry. After selling Shred-Tech in 1995, he purchased Polymer Technologies and grew it from a local plastics manufacturer to a global auto parts company before exiting in 2007. John also served as interim CEO and director of ATS Automation (TSX), which operates 24 global manufacturing facilities, has 4,000 employees and $700 million in sales during a time of management and board renewal in 2007. John was also the lead investor and Chairman of BSM Wireless (TSX-V).

John currently serves as a director of several companies including; Canopy Growth Corp. (TSX) (lead director), DelMar Pharmaceuticals Inc. (lead director), The Royal Canadian Mint, and Strongco Corporation (TSX) (Audit chair). John is a Fellow of the Institute of Charted Accountants and has the Institute of Corporate Directors (ICD.D) designation.

Arlene Dickinson, owner and CEO of Venture Communications, a company she grew from a small, local firm to one of the largest independent agencies in Canada, is also the CEO of District Ventures and Youinc.com. Arlene is a two times best-selling author, accomplished speaker and is best known to Canadians as one of the venture capitalists on the award-winning CBC series Dragons' Den.

Arlene's leadership has been recognized with honours including Canada's Most Powerful Women Top 100, the Pinnacle Award for Entrepreneurial Excellence, as well as PROFIT and Chatelaine's Top 100 Women Business Owners and, is a Marketing Hall of Legends inductee.

"We are very pleased to have John and Arlene join as directors of our Company," said Glen Rehman, "Arlene's exceptional entrepreneurship and marketing expertise, and John's skillset and experience in finance and corporate leadership complement our focus on building market awareness and sales of neuenergy."

NeutriSci has also engaged Skanderbeg Capital Advisors to provide certain investor relations services for a fee of $7,500 per month, with a term expiring on December 31, 2016. The Company has agreed to grant 300,000 incentive stock options to Skanderbeg at an exercise price of 18 cents, vesting quarterly and expiring three years from the date of grant.

To find out more about neuenergy™, visit www.getneuenergy.com.

On Behalf of the Board of Directors of NEUTRISCI INTERNATIONAL INC.

Glen Rehman, President

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

About NeutriSci International Inc.: NeutriSci specializes in the innovation, production and formulation of nutraceutical products. Established in 2009, NeutriSci has focused on the development of several breakthrough nutraceutical products with an initial focus on areas such as heart and cholesterol health, sleep deprivation therapies, immune defense as well as men's prostate and sexual health. NeutriSci continues to build strong relationships and distribution channels for its BluScience™ and NeuEnergy™ products with retailers throughout the United States. NeutriSci is focusing efforts in strengthening sustainable sales models with Convenience, Chain Drug, and Mass Market and Supermarket retailers. For more information, visit: www.neutrisci.com.

Statements in this press release have not been evaluated by the Food and Drug Administration. Products or ingredients are not intended to diagnose, treat, cure or prevent any disease.

Contact Information